Rocket Lab vs. SpaceX: Which Stock is the Better Aerospace Buy?

Rocket Lab reported Q1 2026 revenue of $200.3 million, up 63.5% year over year, with backlog reaching a record $2.2 billion, up 20.2% sequentially. The article highlights additional upside from the upcoming Neutron rocket, the Mynaric acquisition, and a Golden Dome contract win, while noting SpaceX's dominance and imminent IPO as a competitive benchmark. Overall, the piece is constructive on Rocket Lab's growth outlook but still frames both Rocket Lab and SpaceX as high-risk, high-reward aerospace plays.

Analysis

The market is treating this as a two-horse race, but the cleaner second-order read is that Rocket Lab is becoming a defense-systems integrator with a launch sidecar, while SpaceX is increasingly a vertically integrated platform with political optionality. That matters because the valuation inflection for RKLB will come less from launch cadence and more from whether space hardware, optical comms, and national-security payload work can compound into a higher-quality revenue mix; if so, margins can expand before Neutron even flies reliably. RTX’s participation also reduces execution risk in the near term by making Rocket Lab more legible to defense buyers who prefer prime-contract ecosystems over standalone launch vendors.

The near-term catalyst path is asymmetric: months, not days, are what matter. Neutron’s timing is the main binary, but the more underappreciated catalyst is backlog conversion into multi-year visibility; if that backlog keeps stepping up while revenue mix shifts toward higher-margin components, the stock can sustain a premium even without a perfect launch record. The failure mode is also clear: any Neutron slippage or cost-overrun headline would likely compress the multiple quickly because the market is paying for a future launch platform, not a current one.

The contrarian angle is that SpaceX may be the better business but not necessarily the better stock on day one of its listing. A huge private valuation can create a public-market “air-pocket” if IPO supply is large and investor expectations are anchored to perfection; meanwhile RKLB can benefit from being the simpler public proxy for sovereign space spending, especially if capital rotates toward defense-adjacent names with tangible contracts. The hidden winner in either case is the supply chain around optical terminals, propulsion subsystems, and launch insurance/pricing, which should see tighter pricing power as the market prices in a more concentrated launch oligopoly.

Key Decisions for Investors

• Maintain or initiate a tactical long RKLB over the next 3-6 months, with the thesis that defense-backed backlog conversion and hardware mix improvement can re-rate the stock before Neutron is fully de-risked; downside is high if launch execution slips.
• Pair trade idea: long RKLB / short a basket of lower-quality aerospace names with weaker order visibility, to isolate sovereign-space demand and reduce exposure to broad market beta.
• For investors wanting SpaceX exposure, wait for the IPO and avoid chasing day-one strength; if pricing comes at an aggressive premium, use a post-lockup or post-IPO consolidation window rather than opening size immediately.
• Buy near-dated RKLB call spreads only around discrete launch/contract catalysts, not as a core hold; the payoff is best if the market re-prices execution confidence over 1-2 quarters.
• Watch RTX as the lower-volatility way to express spillover from defense-space procurement; if Golden Dome spending becomes real budget flow, RTX should capture more of the value chain than pure-play launch names.